Apricus Biosciences, Inc.
18.05.2011 17:08
---------------------------------------------------------------------------
SAN DIEGO, 2011-05-18 17:07 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that Chief Executive Officer, Dr.
Bassam Damaj, was recently interviewed by CDTV.net, a New York-based financial
network (www.cdtv.net). The interview is available at
http://www.cdtv.net/users/content/apricus-biosciences-nasdaq-apri-ceo-bassam-dam
aj-phd-vitaros-and-femprox.
In the interview, Dr. Damaj reported on a range of corporate activities and
drugs in the company's pipeline, including Apricus Bio's plans for the
commercialization of Vitaros(r), a topical treatment for erectile dysfunction,
in
markets outside of the U.S., including Canada and Europe. Dr. Damaj noted that
Apricus Bio has received approval to market Vitaros(r) in Canada and is
proceeding with manufacturing of the drug. The Company plans to have Vitaros(r)
available to patients in Canada in the second half of 2011, Damaj said.
Like other drugs in Apricus Bio's pipeline, Vitaros(r) uses the company's
patented NexACT(r) technology that allows permeation and enhances the absorption
of a drug through the skin. The active ingredient in Vitaros(r) is alprostadil.
Dr. Damaj also updated progress on Apricus Bio's Femprox(r). Femprox(r) is a
treatment for female sexual arousal disorder ('FSAD'). Apricus Bio owns the
worldwide rights to Femprox(r), a combination of alprostadil and DDAIP. To date,
the Company has completed one Phase II trial in the United States and one Phase
III study in close to 400 women in China, which achieved a statistical 44%
positive response rate as compared to a placebo.
Dr. Damaj also noted the formation of a Male and Female Sexual Dysfunction
Clinical Advisory Board ('Sexual Dysfunction Clinical Advisory Board') as a key
step to further the clinical development of Femprox(r) for FSAD.
Reporting on other drugs in Apricus Bio's pipeline, Dr. Damaj discussed
MycoVa(r)
, which combines an existing, approved drug for onychomycosis (nail fungus),
terbinafine, with NexACT(r) technology that enhances the absorption of the drug
through the skin. In January 2011, the Company announced that an additional
analysis showed that MycoVa(r) is as effective for the treatment of nail fungus
as the current European standard of care for topical therapy.
In addition, Dr. Damaj discussed two other drugs in Apricus Bio's pipeline:
PrevOnco?, a treatment for hepatocellular liver carcinoma, a disease with only
limited treatment options at present, and RayVa? for Raynaud's phenomenon.
Raynaud's phenomenon refers to a disorder in which the fingers or toes (digits)
suddenly experience decreased blood circulation, and is characterized by color
changes of the skin of the digits upon exposure to cold or emotional stress.
About Apricus Biosciences, Inc.
Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has
leveraged the flexibility of its clinically-validated NexACT(r) drug delivery
technology to enable multi-route administration of new and improved compounds
across numerous therapeutic classes.
Revenues and growth are driven from out-licensing of this technology for the
development and commercialization of such compounds to pharmaceutical and
biotechnology companies worldwide. In addition, the Company is seeking to
monetize its existing product pipeline, including its first product, Vitaros(r),
approved in Canada for the treatment of erectile dysfunction, which is
currently expected to be available on the Canadian market in 2011, as well as
compounds in development from pre-clinical through Phase III, currently focused
on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain,
Anti-Infectives, Diabetes and Cosmeceuticals among others.
For further information on Apricus Bio, visit http://www.apricusbio.com and for
information on its subsidiaries please visit www.nexmedusa.com or
www.bio-quant.com. You can also receive information at
http://twitter.com/apricusbio and http://facebook.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to further development products and
product candidates such as Vitaros(r), Femprox(r), MycoVa?, PrevOnco? and
RayVa?,
to successfully commercialize such products and product candidates and to
achieve its other development, commercialization and financial goals. Readers
are cautioned not to place undue reliance on these forward-looking statements
as actual results could differ materially from the forward-looking statements
contained herein. Readers are urged to read the risk factors set forth in the
Company's most recent annual report on Form 10-K, subsequent quarterly reports
filed on Form 10-Q and other filings made with the SEC. Copies of these reports
are available from the SEC's website or without charge from the Company.
Apricus Biosciences, Inc.
Edward Cox, V.P.
Investor Relations & Corporate Development, Apricus Bio, Inc.
(858) 848-4249
ecox@apricusbio.com
Apricus Bio Investor Relations
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
News Source: NASDAQ OMX
18.05.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Apricus Biosciences CEO is Interviewed on CDTV.net
| Source: EQS Group AG